Clayton Dehn is a clinical research physiologist with particular expertise in endocrine disorders, especially those related to fertility and metabolic disturbances. He is a co-inventor of a process and substance for disturbing the inheritance pattern of ion-channelopathic disorders by selectively disabling genetically undesirable sperm cells. He is also the sole author of the first publication cautioning against the risk of SGLT-inhibition inducing ketoacidosis in insulinopenic populations.
Clay has served by gubernatorial appointment to the Arizona Biomedical Research Commission and continues to serve on the editorial board of four peer-reviewed journals. He brings over 15 years of knowledge and experience as a clinical research professional in the pharmaceutical, device, and CRO industries. His experience spans across global drug development, medical affairs, pharmacovigilance and regulatory affairs, and he has a proven track record in building, managing and globalizing medical teams.